As part of the deal, Anupam will buy up to 4,58,03,024 equity shares or 43.30 per cent stake in the formulations company Bliss GVS for over Rs 1,369.51 crore.
In addition, Anupam has an option to buy any or all of the residual equity shares held by the sellers (being up to 51,81,571 equity shares which represent 4.90 per cent stake).
Anupam Rasayan will also make an open offer to buy up to 26 per cent stake from public shareholders of Bliss GVS Pharma for about Rs 829.03 crore.
The total purchase consideration has been financed through a Rs 300 crore term loan and non-controlling non-voting equity instrument for the balance amount, Anupam said.
Bliss GVS Pharma, established in 1984 and listed on the NSE and BSE, has built a strong presence across regulated and semi-regulated international markets, particularly in Africa, Asia and Latin America.
Bliss GVS Pharma has a diversified portfolio of over 150 branded formulations across therapeutic areas such as antimalarial, anti-fungal, anti-bacterial, anti-inflammatory and women’s healthcare. It operates multiple manufacturing facilities in Maharashtra and Daman.
“The acquisition will strategically strengthen our presence across the pharmaceutical value chain, spanning key starting material (KSMs) to finished dosage formulations” Anand Desai, Managing Director, Anupam Rasayan, said in a statement.
Bliss GVS has 6 manufacturing facilities in Palghar, Vevoor and Ambernath across Maharashtra and is the first EU GMP (European Union Good Manufacturing Practice) certified suppositories manufacturer in India, according to an investor presentation.
Bliss GVS had revenue of Rs 927 crore and net profit of Rs 135 crore in FY2026.